1L
ABBV icon

10Elms LLP’s AbbVie ABBV Stock Holding History

10Elms LLP’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.1K Buy
195
+148
+315% +$31.8K 0.02% 241
2026
Q1 		$10.2K Sell
47
-47
-50% -$10.4K 0.01% 402
2025
Q4 		$21.5K Hold
94
– – 0.02% 320
2025
Q3 		$21.8K Hold
94
– – 0.02% 336
2025
Q2 		$17.4K Hold
94
– – 0.02% 358
2025
Q1 		$19.7K Hold
94
– – 0.02% 354
2024
Q4 		$16.7K Buy
+94
New +$17.3K 0.02% 365

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

10Elms LLP's ABBV Position: Q2 2026 in Review

10Elms LLP increased its AbbVie (ABBV) stake by 315% in Q2 2026, buying an estimated $31.8K and bringing the position to 195 shares worth $49.1K. The position accounts for 0.02% of the portfolio, ranked #241.

10Elms LLP first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • 10Elms LLP held 195 shares of AbbVie worth $49.1K as of Q2 2026.
  • 10Elms LLP bought 148 AbbVie shares in Q2 2026, an estimated $31.8K.
  • AbbVie made up 0.02% of 10Elms LLP's portfolio in Q2 2026, its #241 holding.
  • 10Elms LLP first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on 10Elms LLP's 13F filing for Q2 2026, filed 14 Aug 2026.